

Development of Legislation and Other Instruments
Edda Hahlbeck

European Chemicals Agency
Erik van de Plassche
Helsinki

FINLAND

Minority opinion on imiprothrin PT 18 (BPC-21)

The Swedish Competent Authority is seriously concerned by scientific data indicating the mutagenic properties of imiprothrin. These indications have not been sufficiently addressed in the risk assessment of the substance. Therefore, the Swedish Competent Authority cannot agree with the proposal to approve imiprothrin for the use in biocidal products.

Change of genetic code (mutagenicity) is a serious adverse effect with impact for coming generations. Imiprothrin was found to be clearly mutagenic in vitro and as the available in vivo micronucleus and metabolism studies provide insufficient evidence to exclude the mutagenic effect, imiprothrin should be regarded as potentially mutagenic even in vivo.

Since the majority of the BPC proposes to approve imiprothrin in product type 18, Sweden submits a minority opinion.

Yours sincerely

Edda Hahlbeck

Mailing: MAG-0001.22/10/2014

Swedish Chemicals Agency

<i>Mailing address</i>	<i>Visit & delivery</i>	<i>Invoicing address</i>	<i>Phone & fax</i>	<i>Internet</i>	<i>VAT No</i>
Box 2 SE-172 13 Sundbyberg Sweden	Esplanaden 3A SE-172 67 Sundbyberg Sweden	FE 124 SE-838 80 Frösön Sweden	Phone +46 8 519 41 100 Fax +46 8 735 76 98	www.kemi.se kemi@kemi.se	SE202100388001